Andrew Hopkins, Exscientia CEO
Exscientia wants to bring its AI/ML approach into the world of biologics. It's starting with antibodies
Exscientia is looking at breaking out of small molecule R&D.
The UK biotech announced Thursday that it is expanding its R&D efforts into biologics, more …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
